H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (NASDAQ:LGND) on Tuesday, setting a price target of $310, which is approximately 132.72% above the present share price of $133.21.
Pantginis expects Ligand Pharma to post earnings per share (EPS) of $1.84 for the third quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Ligand Pharma, with an average price target of $224.67.
The analysts price targets range from a high of $310 to a low of $174.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $84.68 million and a net profit of $45.74 million. The company's market cap is $2.22 billion.
According to TipRanks.com, H.C. Wainwright analyst Joseph Pantginis is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 21.2% and a 45.16% success rate.
Ligand Pharmaceuticals , Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.